Lupin stated that its US-based unit has inked a pact with Exeltis Inc to promote Solosec, a drug used to treat bacterial vaginosis in women.
As part of the tie up, Exeltis will promote Solosec along with its existing line of women's health products.
Solosec is indicated for the treatment of bacterial vaginosis in adult women and trichomoniasis in adults, a common non-viral, curable sexually transmitted infection in the US.
''This partnership will expand the reach of Solosec, allowing more healthcare providers to be aware of its benefits, and increase access for adult women suffering with bacterial vaginosis and adults with trichomoniasis,'' stated Lupin CEO Vinita Gupta.
UP Budget 2026-27: ₹44,000 Crore For Smart Policing & Law & Order, ₹18,620 Crore For Women & Child Development
Australia's Adam Zampa Becomes Joint Second-Highest Wicket-Taker In T20 World Cup History
Mahindra & Mahindra's Q3 FY26 Profit Jumps 38.5% YoY To ₹5,021 Crore, Revenue Crosses ₹51,500 Crore Milestone On Strong Auto & Farm Growth
UP Budget 2026-27: ₹9,845 Crore Allocated For Justice Department, Fast-Track Courts Made Permanent, Major Sports Infra Push
(With inputs from PTI)
